Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy

SIMPLE SUMMARY: The treatment of resectable stage III non-small-cell lung cancer with N2 lymph node involvement is usually multimodal and is generally based on neoadjuvant chemotherapy +/− radiotherapy followed by surgery, but the cure rate is still low. Immunotherapy based on anti-PD1/PD-L1 immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Mielgo-Rubio, Xabier, Montemuiño, Sara, Jiménez, Unai, Luna, Javier, Cardeña, Ana, Mezquita, Laura, Martín, Margarita, Couñago, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507745/
https://www.ncbi.nlm.nih.gov/pubmed/34638296
http://dx.doi.org/10.3390/cancers13194811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507745/
https://www.ncbi.nlm.nih.gov/pubmed/34638296
http://dx.doi.org/10.3390/cancers13194811

Ejemplares similares